Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Opens in a new tab or window Share on Bluesky ... was 14-19% lower with the two classes as compared with DPP-4 inhibitors, reported researchers led by Elisabetta Patorno, MD, DrPH, of Brigham ...

The first cohort comprised individuals who started and continued either a GLP-1 receptor agonist or DPP-4 inhibitor for the first time between January 1, 2007, and December 31, 2020. The second ...

is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use, according to a study published online February 25 in the Annals of Internal ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 ...

is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use, according to a study published online in the Annals of Internal Medicine.